A Phase 3 interventional study of MSB11022 and Humira® in Psoriasis, Plaque Type Psoriasis and Moderate to Severe Plaque Psoriasis, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 76 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-27.
Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 7th largest by enrollment, is one of 3 that started in 2016, is one of 26 in phase 3, and was the 34th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 443 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under Fresenius Kabi SwissBioSim GmbH, one of the names counted as Fresenius Kabi. Under that name alone:
Fresenius Kabi SwissBioSim GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Fresenius Kabi has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
Drug: MSB11022
Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
Drug: Humira®
Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
Drug: MSB11022
Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
Drug: Humira®
Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
Drug: MSB11022 · Drug: Humira®
Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI-75 response is defined as the percentage of participants who achieved at least a 75% improvement in PASI score from Baseline.
Time frame: Week 16
Percent Change From Baseline in PASI at Week 16
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Percent change from Baseline in PASI score was reported.
Time frame: Baseline (Day 1 of Core Treatment Period), Week 16
Percentage of Participants Who Achieved PASI 50, 90 and 100 at Week 16
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI 50, 90 and 100 response rate at Week 16 is measured as the percentage of participants who achieved at least 50, 90 and 100% improvement from baseline PASI score at Week 16.
Time frame: Week 16
Percentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 24
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 24 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 24.
Time frame: Week 24
Percentage of Participants Who Achieved PASI 50, 75, 90 and 100 at Week 52
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 52 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 52.
Time frame: Week 52
Percent Change From Baseline in PASI at Week 24 and 52
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity.
Time frame: Baseline (Day 1 of Extended Treatment Period), Weeks 24 and 52
Number of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 16
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates Clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates Mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates Moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates Severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
Time frame: Baseline (Day 1 of Core Treatment Period), Week 16
Number of Participants With Change From Baseline in Physician's Global Assessment (PGA) Score to "Clear" or "Almost Clear" at Week 24 and 52
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
Time frame: Baseline (Day 1 of Extended Treatment Period), Week 24 and 52
Time to Achieve PASI 50
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 50% improvement in PASI from baseline was measured.
Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 4
Time to Achieve PASI 75
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 75% improvement in PASI from baseline was measured.
Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 4
Time to Achieve PASI 90
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 90% improvement in PASI from baseline was measured.
Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 4
Time to Achieve PASI 100
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 100% improvement in PASI from baseline was measured.
Time frame: Baseline (Day 1 of Core Treatment Period) up to Month 13.5
Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 16
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
Time frame: Baseline (Day 1 of Core Treatment Period), Week 16
Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 24
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
Time frame: Baseline (Day 1 of Extended Treatment Period), Week 24
Number of Participants With Change in Physician's Global Assessment (PGA) From Baseline at Week 52
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
Time frame: Baseline (Day 1 of Extended Treatment Period), Week 52
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 16
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline (Day 1 of Core Treatment Period) up to Week 16
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs of Special Interest and TEAEs Leading to Death up to Week 54
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline (Day 1 of Extended Treatment Period) up to Week 54
Number of Participants With Clinically Meaningful Differences in Laboratory Values
Based on categories of low, normal, or high according to the laboratory normal ranges, there were no clinically meaningful differences across the treatment groups in the numbers of participants with shifts in Laboratory parameters including hematology, chemistry and urinalysis from normal at Core Baseline to either low or high during the overall treatment period. Clinical meaningful was determined by the investigator.
Time frame: Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54
Number of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 16
Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.
Time frame: Week 16
Number of Participants With Anti-nuclear Antibodies (ANA) and Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Assessments at Week 24, 32, 40 and 52
Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.
Time frame: Week 24, 32, 40 and 52
Number of Participants With Clinically Meaningful Differences in Vital Signs
Number of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.
Time frame: Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54
Number of Participants With Clinically Significant Abnormalities in 12-Electrocardiogram (12-ECG)
Number of participants with clinically significant abnormalities in 12-ECG were reported. Clinical significance was determined by the investigator.
Time frame: Core Treatment Period: Baseline up to 16; Extended Treatment Period: Baseline up to Week 54
Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).
Time frame: Weeks 16
Dermatology Life Quality Index (DLQI) at Week 24 and 52
The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).
Time frame: Week 24 and 52
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 16
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).
Time frame: Week 16
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 24 and 52
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).
Time frame: Week 24 and 52
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on Visual Analogue Scale (VAS) Score at Week 16
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.
Time frame: Week 16
European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on VAS Score at Week 24 and 52
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.
Time frame: Week 24 and 52
Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 16
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Week 16
Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24, and 52
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Week 24 and 52
Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 16
Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.
Time frame: Week 16
Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 24 and 52
Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.
Time frame: Week 24 and 52
Number of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 16
Number of participants with treatment emergent Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab were reported from baseline to week 16. Data was collected using validated bioanalytical method.
Time frame: Week 16
Number of Participants With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab at Week 24, 32, 40 and 52
Number of participants With positive treatment emergent Anti-Drug Antibodies (ADAs) and positive Neutralizing Antibodies (NAbs) to Adalimumab were reported. Data was collected using validated bioanalytical method.
Time frame: Week 24, 32, 40 and 52
Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 16
Anti-Drug Antibodies (ADAs) Titers for adalimumab at week 16 was reported. Data was collected using validated bioanalytical method.
Time frame: Week 16
Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 24, 32, 40 and 52
Anti-Drug Antibodies (ADAs) Titers for adalimumab at Week 24, 32, 40 and 50 was reported. Data was collected using validated bioanalytical method.
Time frame: Week 24, 32, 40 and 52
Observed Serum Concentration at Week 16
Observed serum concentrations at week 16 were reported.
Time frame: Week 16
Observed Serum Concentration at Week 24 and 52
Observed serum concentrations at week 24 and 52 were reported.
Time frame: Week 24 and 52
| Milestone | MSB11022 (Core Treatment Period) | EU-Humira | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|---|---|
| Started | 222 | 221 | 0 | 0 | 0 |
| Treated | 221 | 220 | 0 | 0 | 0 |
| Completed | 213 | 202 | 0 | 0 | 0 |
| Not completed | 9 | 19 | 0 | 0 | 0 |
| Withdrew: Randomized, not treated | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Other un-specified | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 9 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 | 0 |
| Milestone | MSB11022 (Core Treatment Period) | EU-Humira | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 213 | 101 | 101 |
| Completed | 0 | 0 | 195 | 90 | 90 |
| Not completed | 0 | 0 | 18 | 11 | 11 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Other un-specified | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 4 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 8 | 6 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 1 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Percent change from Baseline in PASI score was reported.
| Percent change | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Percent Change From Baseline in PASI at Week 16 | -90.6 ± 11.3 | -91.7 ± 9.9 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI 50, 90 and 100 response rate at Week 16 is measured as the percentage of participants who achieved at least 50, 90 and 100% improvement from baseline PASI score at Week 16.
| Percentage of Participants | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| PASI 50 | 100.0 | 100.0 |
| PASI 90 | 64.0 | 66.0 |
| PASI 100 | 33.0 | 37.2 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 24 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 24.
| Percentage of Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| PASI 50 | 100.0 | 98.9 | 100.0 |
| PASI 75 | 92.5 | 88.3 | 94.6 |
| PASI 90 | 74.0 | 78.7 | 80.4 |
| PASI 100 | 42.5 | 37.2 | 35.9 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI response rate at Week 52 is measured as the percentage of participants who achieved at least 50, 75, 90 and 100% improvement from baseline PASI at Week 52.
| Percentage of Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| PASI 50 | 97.8 | 100.0 | 100.0 |
| PASI 75 | 90.9 | 92.9 | 93.1 |
| PASI 90 | 76.3 | 78.8 | 85.1 |
| PASI 100 | 53.8 | 54.1 | 57.5 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity.
| Percent change | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | -92.9 ± 9.9 | -91.3 ± 12.7 | -94.2 ± 8.2 |
| Week 52 | -92.8 ± 13.6 | -93.9 ± 9.6 | -94.8 ± 9.7 |
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates Clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates Mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates Moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates Severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
| Participants | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Baseline: Moderate; Week 16: Clear | 52 | 51 |
| Baseline: Moderate; Week 16: Almost clear | 76 | 59 |
| Baseline: Severe; Week 16: Clear | 16 | 20 |
| Baseline: Severe; Week 16: Almost clear | 27 | 26 |
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
| Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Baseline: Moderate; Week 24: Clear | 69 | 25 | 25 |
| Baseline: Moderate; Week 24: AlmostClear | 52 | 24 | 31 |
| Baseline: Severe; Week 24: Clear | 18 | 11 | 9 |
| Baseline: Severe; Week 24: Almost Clear | 27 | 14 | 13 |
| Baseline: Moderate; Week 52: Clear | 74 | 29 | 34 |
| Baseline: Moderate; Week 52: AlmostClear | 40 | 13 | 16 |
| Baseline: Severe; Week 52: Clear | 29 | 17 | 16 |
| Baseline: Severe; Week 52: Almost Clear | 15 | 6 | 6 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 50% improvement in PASI from baseline was measured.
| Months | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Time to Achieve PASI 50 | 1.6 ± 0.2 | 1.6 ± 0.2 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 75% improvement in PASI from baseline was measured.
| Months | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Time to Achieve PASI 75 | 2.5 ± 0.2 | 1.7 ± 0.7 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 90% improvement in PASI from baseline was measured.
| Months | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Time to Achieve PASI 90 | 3.4 ± 0.7 | 2.6 ± 1.4 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72, with higher scores reflecting more disease severity. Time to achieve at least 100% improvement in PASI from baseline was measured.
| Month | MSB11022 (Overall Treatment Period) | EU-Humira/EU-Humira (Overall Treatment Period) | EU-Humira/MSB11022 (Overall Treatment Period) |
|---|---|---|---|
| Time to Achieve PASI 100 | 7.2 (0.7 to 11.8) | 7.2 (1.6 to 11.8) | 8.9 (1.6 to 11.8) |
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
| Participants | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Baseline- Moderate; Week 16- Clear | 52 | 51 |
| Baseline- Moderate; Week 16- Almost Clear | 76 | 59 |
| Baseline- Moderate; Week 16- Mild | 16 | 17 |
| Baseline- Moderate; Week 16- Moderate | 2 | 1 |
| Baseline- Severe; Week 16- Clear | 16 | 20 |
| Baseline- Severe; Week 16- Almost Clear | 27 | 26 |
| Baseline- Severe; Week 16- Mild | 12 | 16 |
| Baseline- Severe; Week 16- Moderate | 2 | 1 |
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
| Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Baseline- Moderate; Week 24- Clear | 69 | 25 | 25 |
| Baseline- Moderate; Week 24- Almost Clear | 52 | 24 | 31 |
| Baseline- Moderate; Week 24- Mild | 21 | 10 | 7 |
| Baseline- Moderate; Week 24- Moderate | 2 | 2 | 0 |
| Baseline- Severe; Week 24- Clear | 18 | 11 | 9 |
| Baseline- Severe; Week 24- Almost Clear | 27 | 14 | 13 |
| Baseline- Severe; Week 24- Mild | 9 | 6 | 6 |
| Baseline- Severe; Week 24- Moderate | 2 | 1 | 1 |
| Baseline- Severe; Week 24- Severe | 0 | 1 | 0 |
PGA was assessed relative to baseline condition based on a scale ranged from 0 to 4, where 0 indicates clear condition (no signs of psoriasis, post-inflammatory hyperpigmentation may be present), 1 indicates Almost clear condition (normal to pink coloration of lesion, no thickening and no to minimal \[focal\] scaling), 2 indicates mild condition (pink to light red coloration, just detectable to mild thickening and predominantly fine scaling), 3 indicates moderate condition (dull bright red, clearly distinguishable erythema, clearly distinguishable to moderate thickening and moderate scaling), and 4 indicates severe condition (bright to deep dark red coloration, severe thickening with hard edges and severe/coarse scaling covering almost all or all lesions).
| Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Baseline- Moderate; Week 52- Clear | 74 | 29 | 34 |
| Baseline- Moderate; Week 52- Almost Clear | 40 | 13 | 16 |
| Baseline- Moderate; Week 52- Mild | 17 | 11 | 6 |
| Baseline- Moderate; Week 52- Moderate | 4 | 0 | 4 |
| Baseline- Moderate; Week 52- Missing | 1 | 0 | 0 |
| Baseline- Severe; Week 52- Clear | 29 | 17 | 16 |
| Baseline- Severe; Week 52- Almost Clear | 15 | 6 | 6 |
| Baseline- Severe; Week 52- Mild | 3 | 7 | 3 |
| Baseline- Severe; Week 52- Moderate | 3 | 2 | 2 |
| Baseline- Severe; Week 52- Severe | 1 | 0 | 0 |
| Baseline- Severe; Week 52- Missing | 1 | 0 | 0 |
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Participants with TEAEs | 114 | 117 |
| Participants with Serious TEAEs | 8 | 6 |
| Participants with TEAEs of special interest | 2 | 3 |
| Participants with TEAEs Leading to Death | 0 | 0 |
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Participants with TEAEs | 142 | 65 | 63 |
| Participants with Serious TEAEs | 12 | 3 | 4 |
| Participants with TEAEs of special interest | 10 | 1 | 4 |
| Participants with TEAEs Leading to Death | 0 | 1 | 0 |
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72 with higher scores reflecting more disease severity. The PASI-75 response is defined as the percentage of participants who achieved at least a 75% improvement in PASI score from Baseline.
| Percentage of Participants | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16 | 89.7 | 91.6 |
Based on categories of low, normal, or high according to the laboratory normal ranges, there were no clinically meaningful differences across the treatment groups in the numbers of participants with shifts in Laboratory parameters including hematology, chemistry and urinalysis from normal at Core Baseline to either low or high during the overall treatment period. Clinical meaningful was determined by the investigator.
| Participants | MSB11022 (Core Treatment Period) | MSB11022 (Extended Treatment Period) | EU-Humira | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Differences in Laboratory Values | 0 | 0 | 0 | 0 | 0 |
Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.
| Participants | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Participants with Negative ANA values | 205 | 190 |
| Participants with Positive ANA values | 6 | 10 |
| Participants with Negative anti-ds DNA values | 201 | 186 |
| Participants with Intermediate anti-ds DNA values | 4 | 5 |
| Participants with Positive anti-ds DNA values | 4 | 6 |
Number of participants ANA and anti-ds DNA values were reported. For ANA, positivity is defined as any participants with ANA titer greater than (\>) 1:160 and negativity is defined as ANA titer less than (\<) 1:160. For anti-ds DNA, positivity is defined as any participants with adsDNA \> 15 units per milliliter (U/mL), intermediate category is defined as value between 10 U/mL to 15 U/mL and negativity is defined as adsDNA \< 10 U/mL.
| Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24: Negative ANA | 188 | 89 | 92 |
| Week 32: Negative ANA | 186 | 85 | 88 |
| Week 40: Negative ANA | 178 | 85 | 85 |
| Week 52: Negative ANA | 185 | 84 | 79 |
| Week 24: Positive ANA | 13 | 5 | 5 |
| Week 32: Positive ANA | 13 | 3 | 7 |
| Week 40: Positive ANA | 18 | 6 | 7 |
| Week 52: Positive ANA | 8 | 3 | 8 |
| Week 24: Negative anti-dsDNA | 191 | 89 | 88 |
| Week 32: Negative anti-dsDNA | 184 | 83 | 86 |
| Week 40: Negative anti-dsDNA | 179 | 86 | 84 |
| Week 52: Negative anti-dsDNA | 173 | 81 | 79 |
| Week 24: Positive anti-dsDNA | 8 | 3 | 5 |
| Week 32: Positive anti-dsDNA | 8 | 3 | 5 |
| Week 40: Positive anti-dsDNA | 10 | 3 | 7 |
| Week 52: Positive anti-dsDNA | 11 | 2 | 7 |
| Week 24: Intermediate anti-dsDNA | 3 | 3 | 1 |
| Week 32: Intermediate anti-dsDNA | 7 | 2 | 2 |
| Week 40: Intermediate anti-dsDNA | 7 | 2 | 1 |
| Week 52: Intermediate anti-dsDNA | 8 | 4 | 2 |
Number of participants with clinically meaningful abnormalities in vital signs were reported. Clinical meaningful was determined by the investigator.
| Participants | MSB11022 (Core Treatment Period) | MSB11022 (Extended Treatment Period) | EU-Humira | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Differences in Vital Signs | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinically significant abnormalities in 12-ECG were reported. Clinical significance was determined by the investigator.
| Participants | MSB11022 (Core Treatment Period) | MSB11022 (Extended Treatment Period) | EU-Humira | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in 12-Electrocardiogram (12-ECG) | 0 | 1 | 0 | 1 | 1 |
The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).
| Units on a scale | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Dermatology Life Quality Index (DLQI) at Week 16 | 2.4 ± 3.2 | 2.5 ± 3.7 |
The DLQI is a 10-item validated quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The DLQI measures how much participant's skin problems has affected his life. Responses range from 0=Not at all to 3=Very much. The DLQI total score is the sum of individual 10 items and could range from 0 to 30 (higher score indicated greater negative impact on life).
| Units on a scale | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | 2.5 ± 4.1 | 2.3 ± 4.0 | 2.3 ± 3.9 |
| Week 52 | 3.0 ± 4.7 | 2.1 ± 3.5 | 2.7 ± 4.0 |
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).
| Units on a scale | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Descriptive Score at Week 16 | 0.9 ± 0.1 | 0.9 ± 0.1 |
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The responses are converted into a single index value, with scores ranging from -0.594 to 1 (a higher score indicates better health state).
| Units on a scale | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 |
| Week 52 | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.8 ± 0.1 |
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.
| Units on a scale | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| European Quality of Life 5-Dimensions and 5-Levels Questionnaire (EQ5D-5L) Based on Visual Analogue Scale (VAS) Score at Week 16 | 81.9 ± 13.9 | 83.1 ± 15.0 |
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale, where the participant was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.
| Units on a scale | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | 83.2 ± 14.2 | 84.2 ± 13.7 | 84.3 ± 13.9 |
| Week 52 | 83.5 ± 15.5 | 85.1 ± 13.2 | 82.1 ± 16.1 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| Units on a scale | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 16 | 0.3 ± 0.4 | 0.3 ± 0.4 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| Units on a scale | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | 0.3 ± 0.4 | 0.2 ± 0.5 | 0.4 ± 0.3 |
| Week 52 | 0.3 ± 0.4 | 0.1 ± 0.2 | 0.5 ± 0.3 |
Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.
| millimeter (mm) | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Patient Global Assessment for Joints on Visual Analog Scale (PJA-VAS) at Week 16 | 26.9 ± 28.3 | 24.6 ± 24.3 |
Patient global assessment for joints was measured on a 100 millimeter (mm) VAS scale, where 0 = no pain and 100 = worst possible pain.
| mm | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | 29.7 ± 25.3 | 20.6 ± 27.1 | 24.9 ± 20.5 |
| Week 52 | 25.0 ± 20.3 | 14.7 ± 16.5 | 29.5 ± 19.6 |
Number of participants with treatment emergent Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to Adalimumab were reported from baseline to week 16. Data was collected using validated bioanalytical method.
| Participants | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Participants with ADAs | 186 | 179 |
| Participants with Neutralizing Abs | 70 | 70 |
Number of participants With positive treatment emergent Anti-Drug Antibodies (ADAs) and positive Neutralizing Antibodies (NAbs) to Adalimumab were reported. Data was collected using validated bioanalytical method.
| Participants | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24: ADAs | 185 | 89 | 90 |
| Week 32: ADAs | 170 | 78 | 85 |
| Week 40: ADAs | 161 | 72 | 80 |
| Week 52: ADAs | 162 | 68 | 77 |
| Week 24: NAb | 78 | 42 | 39 |
| Week 32: NAb | 67 | 30 | 32 |
| Week 40: NAb | 70 | 29 | 28 |
| Week 52: NAb | 63 | 29 | 30 |
Anti-Drug Antibodies (ADAs) Titers for adalimumab at week 16 was reported. Data was collected using validated bioanalytical method.
| Titers | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Anti-Drug Antibodies (ADAs) Titers for Adalimumab at Week 16 | 8.0 ± 1 | 8.0 ± 1 |
Anti-Drug Antibodies (ADAs) Titers for adalimumab at Week 24, 32, 40 and 50 was reported. Data was collected using validated bioanalytical method.
| Titers | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | 16.0 (1 to 4096) | 16.0 (1 to 4096) | 16.0 (1 to 4096) |
| Week 32 | 16.0 (1 to 1024) | 16.0 (1 to 8192) | 16.0 (1 to 16384) |
| Week 40 | 16.0 (1 to 8192) | 16.0 (1 to 8192) | 16.0 (1 to 16384) |
| Week 52 | 8.0 (1 to 4096) | 16.0 (1 to 4096) | 8.0 (1 to 4096) |
Observed serum concentrations at week 16 were reported.
| Nanogram per milliliter (ng/mL) | MSB11022 (Core Treatment Period) | EU-Humira |
|---|---|---|
| Observed Serum Concentration at Week 16 | 6990 ± 4504 | 6410 ± 4152 |
Observed serum concentrations at week 24 and 52 were reported.
| ng/mL | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|
| Week 24 | 6240 ± 4569 | 5870 ± 4516 | 6430 ± 4610 |
| Week 52 | 6910 ± 5750 | 5930 ± 4529 | 6600 ± 5394 |
Collected over Core Treatment period: Baseline up to Week 16; Extended Treatment Period: Baseline up to Week 54. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSB11022 (Core Treatment Period) | 0/221 (0%) | 8/221 (3.6%) | 30/221 (13.6%) |
| EU-Humira | 0/220 (0%) | 6/220 (2.7%) | 34/220 (15.5%) |
| MSB11022 (Extended Treatment Period) | 0/213 (0%) | 12/213 (5.6%) | 59/213 (27.7%) |
| EU-Humira/EU-Humira | 1/101 (1%) | 3/101 (3%) | 32/101 (31.7%) |
| EU-Humira/MSB11022 | 0/101 (0%) | 4/101 (4%) | 25/101 (24.8%) |
| Event | MSB11022 (Core Treatment Period) | EU-Humira | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/221 | 0/220 | 0/213 | 2/101 | 0/101 |
| Hypertensive cardiomyopathyCardiac disorders | 0/221 | 0/220 | 0/213 | 1/101 | 0/101 |
| Mitral valve incompetenceCardiac disorders | 0/221 | 0/220 | 0/213 | 1/101 | 0/101 |
| Myocardial infarctionCardiac disorders | 0/221 | 0/220 | 0/213 | 0/101 | 1/101 |
| Conjunctival cystEye disorders | 0/221 | 0/220 | 0/213 | 0/101 | 1/101 |
| AppendicitisInfections and infestations | 0/221 | 0/220 | 0/213 | 0/101 | 1/101 |
| PneumoniaInfections and infestations | 0/221 | 0/220 | 0/213 | 1/101 | 0/101 |
| Staphylococcal abscessInfections and infestations | 0/221 | 0/220 | 0/213 | 0/101 | 1/101 |
| Brain oedemaNervous system disorders | 0/221 | 0/220 | 0/213 | 1/101 | 0/101 |
| Cerebral haematomaNervous system disorders | 0/221 | 0/220 | 0/213 | 1/101 | 0/101 |
| Event | MSB11022 (Core Treatment Period) | EU-Humira | MSB11022 (Extended Treatment Period) | EU-Humira/EU-Humira | EU-Humira/MSB11022 |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 13/221 | 15/220 | 31/213 | 12/101 | 16/101 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/221 | 0/220 | 11/213 | 10/101 | 3/101 |
| Injection site erythemaGeneral disorders | 11/221 | 13/220 | 9/213 | 5/101 | 6/101 |
| Injection site painGeneral disorders | 11/221 | 11/220 | 12/213 | 4/101 | 5/101 |
| Upper respiratory tract infectionInfections and infestations | 0/221 | 0/220 | 11/213 | 5/101 | 4/101 |
| Age, Continuous(years) | MSB11022 (Core Treatment Period) | EU-Humira | Total |
|---|---|---|---|
| Mean | 44.5 ± 12.8 | 42.7 ± 12.0 | 43.6 ± 12.5 |
| Sex: Female, Male(Participants) | MSB11022 (Core Treatment Period) | EU-Humira | Total |
|---|---|---|---|
| Female | 75 | 73 | 148 |
| Male | 147 | 148 | 295 |
| Race(Participants) | MSB11022 (Core Treatment Period) | EU-Humira | Total |
|---|---|---|---|
| White | 205 | 200 | 405 |
| Black or African American | 2 | 1 | 3 |
| Asian | 5 | 9 | 14 |
| American Indian or Alaska Native | 10 | 8 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 1 | 1 |
| Missing/Not collected at this site | 0 | 2 | 2 |
| Ethnicity(Participants) | MSB11022 (Core Treatment Period) | EU-Humira | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 23 | 46 |
| Not Hispanic or Latino | 199 | 196 | 395 |
| Missing | 0 | 2 | 2 |
Ran from Feb 2016 to primary completion in Dec 2016, 10 months.
Results were first posted in Feb 2019, 2 years 1 month after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
Fresenius Kabi SwissBioSim GmbH →